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Background: Brucellosis causes substantial morbidity among humans and their livestock. There are few robust
estimates of the incidence of brucellosis in sub-Saharan Africa. Using cases identified through sentinel hospital
surveillance and health care utilization data, we estimated the incidence of brucellosis in Moshi Urban and
Moshi Rural Districts, Kilimanjaro Region, Tanzania, for the periods 2007–2008 and 2012–2014.
Methods: Cases were identified among febrile patients at two sentinel hospitals and were defined as having
either a 4-fold increase in Brucella microscopic agglutination test titres between acute and convalescent ser-
um or a blood culture positive for Brucella spp. Findings from a health care utilization survey were used to esti-
mate multipliers to account for cases not seen at sentinel hospitals.
Results: Of 585 patients enrolled in the period 2007–2008, 13 (2.2%) had brucellosis. Among 1095 patients
enrolled in the period 2012–2014, 32 (2.9%) had brucellosis. We estimated an incidence (range based on sen-
sitivity analysis) of brucellosis of 35 (range 32–93) cases per 100 000 persons annually in the period
2007–2008 and 33 (range 30–89) cases per 100 000 persons annually in the period 2012–2014.
Conclusions: We found a moderate incidence of brucellosis in northern Tanzania, suggesting that the disease
is endemic and an important human health problem in this area.
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Introduction
Brucellosis is a zoonosis and can cause fever and substantial mor-
bidity among humans and their livestock.1 Estimating the burden
of human brucellosis is challenging because of underrecognition
by health care providers, limited availability of appropriate labora-
tory diagnostics and difficult access to health care among popula-
tions most at risk for brucellosis.2 As a consequence, the incidence
of brucellosis is uncertain in many sub-Saharan African countries,
resulting in few data to guide the allocation of resources for public
health interventions and disease control.3
Despite the lack of a comprehensive assessment of brucellosis
incidence, several studies demonstrate that Brucella infection is
not uncommon in Tanzania, and more generally in sub-Saharan
Africa.4,5 Bouley et al.4 reported brucellosis among 16 (3.5%) of
870 febrile Tanzanian patients, while Shellings et al.5 estimated a
brucellosis seroprevalence of 3.8% among nomadic communities
in Chad. Infections with Brucella are characterized by a low case
fatality ratio of approximately 1%, but brucellosis may progress to
chronic musculoskeletal, neurologic and cardiovascular complica-
tions in humans.1,6 Furthermore, since brucellosis is associated
with abortion, premature birth and reduced milk production
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among animals, brucellosis can have a negative economic
impact in low-resource settings where livestock is a source of
food security and income.7 Estimating the incidence of brucel-
losis in sub-Saharan Africa is a key element for determining the
disease burden and the allocation of disease control resources.
Utilizing data from two rounds of sentinel site surveillance and
health care utilization data, we aimed to estimate the longitu-
dinal incidence of human brucellosis in Moshi Urban and Moshi
Rural Districts, Kilimanjaro Region, Tanzania during the periods
2007–2008 and 2012–2014.
Materials and methods
Study design
A widely used multiplier study method was applied to estimate
the incidence of brucellosis.8–10 Our study utilized hospital-
based fever surveillance at the two major referral hospitals in
the Kilimanjaro Region of Tanzania and a health care utilization
survey performed in two districts of the Kilimanjaro Region, the
Moshi Urban District and the Moshi Rural District.
Hospital-based fever surveillance
Setting
Fever surveillance was conducted at two referral hospitals in
Moshi. Moshi is situated in the Kilimanjaro Region of Tanzania at
an elevation of approximately 890m (Figure 1). The climate in
Moshi is tropical, with rainy seasons from October through
December and March through May. Aside from urban Moshi, the
region is rural. The Kilimanjaro Christian Medical Centre (KCMC) is
a 450-bed hospital and the zonal referral centre for several
regions in northern Tanzania. Mawenzi Regional Referral Hospital
(MRRH) is a 300-bed hospital and the referral centre for the
Kilimanjaro Region.11
Study population
Adult and paediatric febrile patients were prospectively enrolled
at KCMC and MRRH from 17 September 2007 through 31 August
2008 and from 20 February 2012 through 28 May 2014.12–14
During the period 2007–2008 only inpatients were involved in
the study: specifically, consecutive febrile adult and paediatric
inpatients at KCMC and consecutive febrile adult inpatients at
MRRH were included in the study within 24 h of hospital presen-
tation. During the period 2012–2014 both inpatients and outpa-
tients were involved in the study: specifically, consecutive febrile
adult inpatients at KCMC, consecutive febrile adult and paediat-
ric inpatients at MRRH and every second febrile adult or paediat-
ric outpatient at MRRH were included in the study within 24 h of
hospital presentation. Fever was defined as follows: (1) period
2007–2008, adult inpatients: oral temperature ≥38.0°C; (2) peri-
od 2007–2008, paediatric inpatients: history of fever in the past
48 h, an axillary temperature ≥37.5°C or a rectal temperature
≥38.0°C; (3) period 2012–2014, inpatients: a history of fever
within the previous 72 h, an axillary temperature >37.5°C or a
tympanic, oral or rectal temperature ≥38.0°C; (4) period
2012–2014, outpatients: an axillary temperature >37.5°C or a
tympanic, oral or rectal temperature ≥38.0°C.12–14
Study procedures
Enrolment occurred Monday through Friday. Demographic infor-
mation, including the participant’s district and village of resi-
dence, was collected. BacT/ALERT (bioMerieux, Marcy l’Etoile,
France) blood culture bottles were inoculated (Standard Aerobic
for adults and Paediatric Fastidious Antibiotic Neutralization for
participants <13 years of age) and acute sera were collected. A
convalescent serum sample was collected 4–6 weeks after
study enrolment. Interhospital transfer was recorded only for
the period 2007–2008.
Diagnosis of brucellosis
Acute and convalescent serum samples were sent to the US
Centers for Disease Control and Prevention (CDC) for serologic ana-
lysis for brucellosis by microscopic agglutination test (MAT) using
standardized Brucella abortus strain 1119-3 killed antigen (National
Veterinary Services Laboratory [NVSL], Ames, IA, USA) at a 1:25
working dilution. Samples were inoculated into U-bottom plates
and incubated at 26°C. High-positive, low-positive and negative
control sera (NVSL) were also included for each test run. Results
were read on a Scienceware Plate Reader (Bel-Art Products,
Wayne, NJ, USA). Inoculated blood culture bottles were loaded
into the BacT/ALERT 3D Microbial Detection System (bioMerieux,
Marcy l’Etoile, France), where they were incubated for 5 days.15,16
Cases were defined by a 4-fold or greater increase in the B. abortus
MAT antibody titre between acute and convalescent serum or by
isolation of Brucella spp. from blood cultures.17
Health care utilization survey
A health care utilization survey was performed in the Moshi
Urban District (population 184 292) and Moshi Rural District
(population 466 737) of the Kilimanjaro Region between 13
Figure 1. Africa, Tanzania and Kilimanjaro Region. Moshi Rural District
shown in dark grey and Moshi Urban District in black in the Kilimanjaro
Region inset. Modified from Biggs HM, Hertz JT, Munishi OM, et al.
Estimating leptospirosis incidence using hospital-based surveillance and
a population-based health care utilization survey in Tanzania. PLoS Negl
Trop Dis. 2013;7(12):e2589.
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June 2011 and 22 July 2011, as previously described.18 The
Moshi Urban and Moshi Rural Districts were defined based on
the administrative divisions of Tanzania. Briefly, 30 (66.7%) of
the 45 wards were selected using a population-weighted ran-
dom sampling method. In each selected ward a starting point
was chosen arbitrarily while touring the ward on foot by a
member of the study team who was not previously familiar
with the area. A direction was similarly chosen and the first 27
households along that direction from the starting point were
included in the survey. Questions relating to health care–seeking
behaviour in the event of febrile illness were used to identify
participants likely to present to KCMC or MRRH. These questions
included, ‘To which facility would you go if you were unwell with
a fever lasting ≥3 days?’.11,18
Incidence calculation
Incidence calculation was based on the absolute number of
hospital patients meeting the brucellosis case definition and on
multipliers derived from the fever surveillance and the health
care utilization survey. Multipliers account for brucellosis cases
that were potentially missed in the stages of reporting (Figure 2)
and are the multiplicative inverse of the relevant proportions.
Multipliers
The following multipliers were calculated: (1) KCMC multiplier
and MRRH multiplier, to account for health care–seeking prefer-
ences and cases potentially missed due to selection of health
care facilities not under surveillance. The KCMC multiplier and
MRRH multiplier were derived based on head-of-household
responses to the question: ‘What will you do if a member of this
household has elevated body temperature for ≥3 days?’; (2)
referral adjustment multiplier for the period 2007–2008, to
adjust for patients transferred to KCMC from another inpatient
hospital, given that transfer may not reflect a patient’s prefer-
ence of health care facility; (3) enrolment multiplier, to account
for patients who were eligible but did not enrol in the hospital-
based fever surveillance for any reason; (4) blood drawn multi-
plier, to account for patients for whom the blood volume
obtained was insufficient for brucellosis serology; (5) study dur-
ation multiplier for the period 2012–2014, to calculate annual
incidence from a study that enrolled for 27 months; (6) time
multiplier, to account for fever surveillance enrolment 5 of 7
days of the week and (7) agglutination test specificity multiplier,
to account for MAT specificity (96.1%).19
Population denominators
Brucellosis incidence was calculated by age group as follows:
0–4, 5–14 and ≥15 years. As age-specific population data were
not available from the 2012 Tanzania National Census, we
multiplied age-specific proportions from the 2002 Tanzania
National Census by the 2012 Tanzania National Census popula-
tion total to estimate age-specific populations.11,20–21
Sensitivity analysis
To assess the sensitivity of our incidence estimates, we per-
formed a one-way sensitivity analysis by varying (1) hospital
multipliers according to answers to alternative relevant ques-
tions in the health care utilization survey that might also reflect
the behaviour of participants, (2) diagnostic test multipliers by
using a range of alternative sensitivity and specificity values for
agglutination tests from the published literature22–25 and (3)
population denominators for the period 2007–2008 by estimat-
ing the Moshi Urban and Moshi Rural populations in the period
Figure 2. Surveillance pyramid showing multipliers used to account for incomplete case identification. Modified from Biggs HM, Hertz JT, Munishi OM,
et al. Estimating leptospirosis incidence using hospital-based surveillance and a population-based health care utilization survey in Tanzania. PLoS
Negl Trop Dis 2013;7(12):e258.
M. Carugati et al.
138
Downloaded from https://academic.oup.com/trstmh/article-abstract/112/3/136/4985557
by guest
on 22 May 2018
2007–2008 as the mean of the 2002 population and the 2012
population in Moshi Urban and Moshi Rural Districts.11
Statistical analysis
Data were entered into an Access database (Microsoft, Redmond,
WA, USA) using the Cardiff Teleform system (Cardiff, Vista, CA, USA).
Incidence calculations were done using Excel 2016 (Microsoft).
Other analyses were performed using SAS Enterprise Guide, version
7.1 (SAS Institute, Cary, NC, USA).
Results
Hospital-based fever surveillance
In the period 2007–2008, 1310 patients were eligible for enrol-
ment and 870 (66.4%) participated in the study. Of these parti-
cipants, 588 (67.6%) were from the Moshi Urban or Moshi Rural
Districts. Blood cultures were collected for 585 (99.5%) of these
588 participants. All the participants were inpatients. Of these,
249 (42.6%) were aged 0–4 years, 58 (9.9%) 5-14 years, and
278 (47.5%) ≥15 years. None had a blood culture positive for
Brucella spp. Among 585 patients residing in the study area and
for whom a blood culture was collected, 314 (53.7%) had paired
sera tested. Of those with paired sera tested, 13 (4.1%) of 314
met the case definition for brucellosis.
During the period 2012–2014, 2962 patients were eligible for
enrolment and 1416 (47.8%) participated in the study. Of these
participants, 1115 (78.7%) were from the Moshi Urban or Moshi
Rural Districts. Blood cultures were collected for 1095 (98.2%)
of 1115 participants. Outpatients accounted for 467 (42.6%) of
the participants for whom blood cultures were collected. Of
the 1,095 participants, 409 (37.4%) were aged 0-4 years, 110
(10.0%) 5–14 years, and 576 (52.6%) ≥15 years. None had a
blood culture positive for Brucella spp. Of those residing in the
study area and for whom a blood culture was collected, 632
(57.7%) had paired sera tested. Of those with paired sera
tested, 32 (5.0%) met the case definition for brucellosis. Of the
32 patients with a diagnosis of brucellosis, 9 (28.1%) were out-
patients. Overall, 45 patients had a laboratory-confirmed diag-
nosis of brucellosis in the study periods. Of these, 41 (91.1%)
had a syndrome clinically compatible with brucellosis, as
defined by the US CDC. Among the 45 brucellosis cases identi-
fied in the two study periods, the median duration of illness
before presentation was 5 days (interquartile range [IQR] 4–7)
in the period 2007–2008 and 7 days (IQR 3–14) in the period
2012–2014. For all 45 brucellosis cases identified from both the
study periods, brucellosis was never recorded as a clinical diagno-
sis by the treating physician, neither at admission or at discharge.
The most common clinical diagnoses were as follows: 20 (44.4%)
malaria, 6 (13.3%) pneumonia, 4 (8.9%) septicaemia, 4 (8.9%)
gastroenteritis, 3 (6.7%) upper respiratory tract infection and 3
(6.7%) urinary tract infection. The five remaining cases were
given the following clinical diagnoses by the treating physician:
anaemia, diabetes, meningitis, paratyphoid fever and pruritus. In
both study periods, none of the patients with a laboratory diag-
nosis of brucellosis received one of the recommended first-line
combination antibacterial regimens (doxycycline plus aminogly-
coside or doxycycline plus rifampin); five patients with a labora-
tory diagnosis of brucellosis (one in the period 2007–2008 and
four in the period 2012–2014) were treated with ciprofloxacin
monotherapy, but the duration of the treatment is unknown. Of
the patients who did not have a laboratory diagnosis of brucel-
losis, only one was treated with a recommended first-line anti-
microbial regimen for brucellosis (doxycycline plus gentamicin).
Health care utilization survey
A total of 810 households were sampled, comprising 3919 house-
hold members. All households had at least one member ≥15 years
of age, 361 (44.6%) had at least one member between 5 and 14
years of age and 198 (24.4%) had at least one member <5 years
of age. Table 1 illustrates the responses to the question ‘What will
you do if a household member has a fever for ≥3 days?’.
Incidence calculation and sensitivity analysis
Multipliers were calculated (Table 2). By applying multipliers to
confirmed cases, we estimated an overall incidence of brucel-
losis of 35 cases per 100 000 persons annually in the period
2007–2008 (Table 3) and 33 cases per 100 000 persons annu-
ally in the period 2012–2014 (Table 4). Brucellosis incidence
appeared to be higher in the Moshi Urban District than the
Moshi Rural District in the period 2007–2008, at 53 cases per
100 000 persons annually compared with 25 cases per 100 000
persons annually, respectively, and in the period 2012–2014 at
88 cases per 100 000 persons annually compared with 14 cases
per 100 000 persons annually, respectively. The variation of hos-
pital multipliers, diagnostic test multipliers and population
denominators in the period 2007–2008 resulted in an annual
brucellosis incidence ranging from 32 to 93 cases per 100 000
population. The variation of hospital multipliers and diagnostic
test multipliers in the period 2012–2014 resulted in an annual
brucellosis incidence ranging from 30 to 89 cases per 100 000
Table 1. Responses to the question in the health care utilization survey, ‘What will you do if a household member has a fever for ≥3 days?’
Age (years) Household
members, n
Household members
going to KCMC, n (%)
Household members
going to MRRH, n (%)
Household members not going
to KCMC or MRRH, n (%)
<5 198 17 (8.6) 67 (33.8) 114 (57.6)
5–14 361 10 (2.8) 137 (38.0) 214 (59.3)
≥15 810 35 (4.3) 299 (36.9) 476 (58.8)
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population. In both study periods the highest incidence esti-
mates were obtained when hospital multipliers were derived
from the question ‘What will you do if a household member has
a fever?’. In contrast, the lowest brucellosis incidence estimates
were associated with the use of the lowest plausible MAT speci-
ficity estimate (Table 5).
Discussion
We found a moderate incidence of brucellosis in the Kilimanjaro
Region of Tanzania of 35 cases per 100000 in the period 2007–2008
and 33 cases per 100 000 in the period 2012–2014. These esti-
mates suggest that brucellosis is stably endemic in the study area
Table 2. Derivation of multipliers to estimate the incidence of brucellosis in the Moshi Rural and Moshi Urban Districts, Kilimanjaro Region,
Tanzania
Multiplier equation Multiplier for period
2007–2008 2012–2014
KCMC multiplier =no. of households interviewed/no. of households seeking care at
KCMC for fever ≥3 daysage <5 years 198/17 11.63 198/17 11.63
age 5–14 years 361/10 36.10 361/10 36.10
age ≥15 years 810/35 23.10 810/35 23.10
MRRH multiplier =no. of households interviewed/no. of households seeking care at
MRRH for fever ≥3 daysage <5 years 198/67 3.00 198/67 3.00
age 5–14 years 361/137 2.64 361/137 2.64
age ≥15 years 810/299 2.71 810/299 2.71
Referral adjustment multiplier =no. of study patients admitted to KCMC without referral from
another facility/no. of patients admitted to KCMCage <5 years 166/249 0.67 N/A N/A
age 5–14 years 40/55 0.80 N/A N/A
age ≥15 years 72/94 0.77 N/A N/A
Enrolment multiplier =no. of eligible patients/no. of patients enrolled in fever surveillance 1310/870 1.51 2394/1420 1.69
Blood drawn multiplier =no. of patients included in the incidence study/no. of patients for
whom serology was performedage <5 years 249/232 1.07 409/335 1.22
age 5–14 years 58/57 1.02 110/108 1.02
age ≥15 years 278/274 1.01 576/554 1.04
Study duration multiplier =no. of months per year/study duration (in months) N/Aa N/A 12/27 0.44
Time multiplier =no. of days in a week/no. of enrolment days per week 7/5 1.40 7/5 1.40
Paired sera multiplier =no. of patients included in the incidence study for whom serum
was collected/no. of patients included in the incidence study with
paired sera
563/314 1.79 997/632 1.58
AT specificity multiplier =specificity 0.96 0.96 0.96 0.96
AT: agglutination test; N/A: not applicable.
aStudy duration multiplier not applicable for 2007–2008 study period because the study enrolment lasted 1 year and 15 days, therefore it was
not necessary to annualize the case numbers.
Table 3. Annual incidence of brucellosis in the Moshi Rural and Moshi Urban Districts, Kilimanjaro Region, Tanzania, 2007–2008, based on the
question, ‘To which facility would you go if you were unwell with a fever lasting ≥3 days?’
Age group (year) KCMC crude
cases
KCMC adjusted
cases
MRRH crude
cases
MRRH adjusted
cases
Estimated
annual cases
Population Annual incidence
per 100 000
<5 4 30 N/A N/A 125 82 016 153
5–14 N/A N/A N/A N/A 0 179 387 0
≥15 2 34 7 19 105 389 625 27
Overall 230 651 028 35
KCMC: Kilimanjaro Christian Medical Centre; MRRH: Mawenzi Regional Referral Hospital; N/A: not applicable.
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and provide important epidemiologic information on the human
health impact of this disease in the Kilimanjaro Region.26
Our study is among the first to estimate brucellosis incidence
in a sub-Saharan African country based on health care facility–
based surveillance and health care utilization data.26 While
there are a number of studies of brucellosis prevalence, as far
as we know the only available incidence estimates of brucellosis
in sub-Saharan Africa come from Chad, where an incidence of
35 cases per 100 000 person-years was derived from a sero-
prevalence of 3.8%, assuming a fixed proportion of clinical cases
among seropositives (10.0%) and a fixed duration of seropositiv-
ity.5 We suggest that our study based on detection of cases
over many years of surveillance provides a more robust means
of estimating incidence and we hope that similar studies will be
undertaken elsewhere in sub-Saharan Africa. Furthermore, the
sensitivity analysis showed that when the uncertainty in key
parameters was considered, the incidence estimates did not
vary substantially. Our estimate was most sensitive to varying
the health care utilization survey questions about fever. The
higher incidence estimates derived by investigating health care–
seeking behaviour for fever of unspecified duration and for fever
lasting <3 days reflects the fact that patients are less likely to
present to tertiary hospitals in cases of shorter durations of
fever. We think that the estimates based on fever of unspecified
duration and on fever lasting <3 days are less accurate than our
final estimate, as 85% of the patients diagnosed with brucel-
losis reported a fever of at least 3 days.11 These durations are
compatible with data available in the literature.27
Table 4. Annual incidence of brucellosis in the Moshi Rural and Moshi Urban Districts, Kilimanjaro Region, Tanzania, 2012–14, based on the
question, ‘To which facility would you go if you were unwell with a fever lasting ≥3 days?’
Age group (year) KCMC crude
cases
KCMC adjusted
cases
MRRH crude
cases
MRRH adjusted
cases
Estimated
annual cases
Population Annual incidence
per 100 000
<5 N/A N/A 3 11 22 82 016 27
5–14 N/A N/A 2 10 17 179 387 9
≥15 6 133 21 72 177 389 625 45
Overall 216 651 028 33
N/A: not applicable.
Table 5. Sensitivity analysis to assess the precision of brucellosis incidence estimates in the Moshi Urban and Moshi Rural Districts, Kilimanjaro
Region, Tanzania, 2007–2008 and 2012–2014, based on the variation of hospital multipliers, diagnostic test multipliers and population
denominators
Estimated incidence of
brucellosis per 100 000
population per year
Period
2007–2008
Period
2012–2014
Variation in hospital multipliers based on varying the question from the health care utilization surveya
Question: What will you do if a household member has a fever lasting <3 days? 66 56
Question: What will you do if a household member has a fever (duration not specified)? 93 89
Variations in estimation of specificity of agglutination test
Lowest plausible estimate 32 30
Single titre ≥1:160: 88%
Highest plausible estimate 37 35
Single titre ≥1:160: 100%
Variations in census data
Total population for the period 2007–2008 is the mean of the census population in 2002 and in 2012 (=598 098) 38 N/A
N/A: not applicable.
aHospital multipliers are derived from questions included in the health care utilization survey (see Methods) and account for cases potentially
not captured by our surveillance sites (KCMC and MRRH).
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Our study raises several other interesting points. First, our
estimates of brucellosis incidence varied substantially among
age groups. While these variations may be related to inad-
equate power or study design, the apparent low incidence of
brucellosis among those 5–14 years of age may be due to differ-
ences in exposure or host factors by age. Second, we estimated
an apparently higher incidence of brucellosis in the Moshi Urban
District compared with the Moshi Rural District. It is important
to note that this estimate is based on the assumption that the
age distribution was similar in the Moshi Urban and Moshi Rural
Districts during the two study periods. If true, this finding sug-
gests that urban residents may be at higher risk of exposure to
Brucella spp. than rural persons in this area, perhaps pointing to
exposure pathways that involve wide food distribution networks.
Third, brucellosis was never recorded as a clinical diagnosis by
the treating physician, neither at admission nor at discharge.
This is likely due to a low index of suspicion for brucellosis
among treating physicians, compounded by the lack of accurate
diagnostic tests for brucellosis. Finally, our study highlights that
employing rigorous serologic diagnostics is important for epide-
miologic research on brucellosis. While culture of blood, bone
marrow and other normally sterile sites provides the most spe-
cific diagnosis, the limited sensitivity of blood culture for
Brucella spp. detection is well-documented.28 Relying solely on
blood culture for surveillance of brucellosis may lead to sub-
stantial underestimates of incidence.
Our estimates represent our best effort to evaluate the inci-
dence of human brucellosis in sub-Saharan Africa, but we rec-
ognize a number of limitations. First, our case definition of
brucellosis was based only on laboratory parameters, since
comprehensive clinical information were lacking for the study
period 2007–2008. Despite the fact that not all variables
included in the CDC case definition of brucellosis were assessed
during the study period 2007–2008, 41 (91.1%) of the 45
laboratory-confirmed brucellosis cases had a syndrome clinically
compatible with brucellosis as defined by the CDC. While inci-
dence is fundamental to understanding the burden of brucel-
losis, we did not evaluate other components of disease burden,
such as attributed disability and case:fatality ratio. Specifically,
the assessment of disability was beyond the scope of this
research, and case fatality ratios were not estimated because
no patients with a blood culture positive for Brucella spp. went
on to die of their illness, and serologic case confirmation
requires survival for collection of serum 4–6 weeks after enrol-
ment. The multiplier method employed in this study has been
described and applied to estimate the incidence of febrile ill-
nesses in settings where resources and infrastructure for active
population-based surveillance are insufficient.8–10,29 However,
several assumptions were made in the derivation and use of
multipliers. In particular, we assume that patients presenting at
the study sites were representative of the household members
sampled in the health care utilization survey and that the care-
seeking behaviour of those surveyed was representative of the
overall population.11 Finally, the assessment of risk factors for
human brucellosis (e.g., occupational exposures, foodborne
exposures, livestock husbandry practices, etc.) as well as evalu-
ation of the prevalence of brucellosis among animals in the
study area were beyond the scope of this project.30
Conclusions
Our study highlights that brucellosis is endemic in the Kilimanjaro
Region of Tanzania. Efforts to identify the reservoirs, sources and
modes of transmission are needed to inform control strategies.
Furthermore, our study reveals the importance of developing clin-
ical risk stratification algorithms and brucellosis diagnostic cap-
acity to inform the treatment of febrile illness in Tanzania and
elsewhere in sub-Saharan Africa.
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